Anti-VEGF-A Affects the Angiogenic Properties of Tumor-Derived Microparticles (original) (raw)
Figure 1
Exposing tumor cells to anti-VEGF-A antibodies reduces the level of VEGF-A in TMPs without affecting the number of TMPs.
(A) A representative flow cytometry dotplot for TMP quantification. TMPs are approximately 1 µm, and counting beads are 7.35 µm. The number of TMPs per sample was calculated as the ratio between the number of events collected in the counting beads gate and the number of events collected in the TMPs gate over the total number of counting beads loaded in the sample. (B) EMT/6, 4T1 and MDA-MB231 breast carcinoma cells were either left untreated or exposed to 2 µg/ml B20 antibody for 48 h. TMPs were purified from conditioned medium and quantified by flow cytometry. Shown are the means ± S.D. of triplicates. (C) An equal number of TMPs (100,000) from untreated or B-20-exposed EMT/6, 4T1 and MDA-MB231 breast carcinoma cells were used to quantify the level of VEGF-A by ELISA. In some experiments control for B20 antibodies was used in a form of IgG in culture. Shown are the means ± S.D. of triplicates. **, 0.01>p>0.001.